This site is intended for health professionals only

InSightec Ltd announces US$15 million investment round

teaser

InSightec Ltd has reported that it has closed an internal round of financing totaling US$15 million from its existing investors.

Elbit Imaging Ltd (NASDAQ: EMITF) (“EI”) has invested US$7.5M on March 18, 2009. Additional US$7.5M would be invested no later than 12 months following the date hereof by its existing investors.

The investment will take the form of Preferred Shares B, which are convertible to InSightec’s ordinary shares subject to the fulfillment of certain conditions stipulated in the agreement.

InSightec reported that the funds would be used to expand its research and development efforts, for marketing and sales activities, and for general corporate purposes.

InSightec’s President and CEO, Dr. Kobi Vortman said, “We are very proud in the ongoing trust we are receiving from our investors that share our vision that this technology is the enabler of the next generation operating room that will be a non invasive and outpatient operating room.”

“The ExAblate(R) 2000 treatments of uterine fibroids continue to grow globally with excellent clinical results driving market adoption in more than 70 leading sites globally and over 4500 women treated worldwide. In parallel, InSightec is expanding its research into the oncology areas: bone metastases, prostate cancer, breast cancer, liver tumors and brain tumors. Recent
publications have shown that Magnetic Resonance guided Focused Ultrasound (MRgFUS) with the ExAblate(R) system has the potential to be an effective noninvasive pain relieving treatment for tumors that have spread to the bones (bone metastases). InSightec is conducting a phase III pivotal trial for the treatment of pain palliation of bone metastases. In addition, a Fertility Enhancement study is being performed evaluating the potential of ExAblate fibroids’ treatments to enhance fertility when other potential causes of women’s infertility have been ruled out.

“The investment will allow acceleration of the technical and clinical research for oncology applications providing improved care for patients around the world.”

InSightec






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x